Mayne Pharma says it expects to return to positive EBITDA and cash generation in FY24.Drilling down in its women's health division, the company will work to complete the integration of the news in-licensed women's health assets.In its dermatology business, the company is planning capital-light, accretive business arrangements, including further developing its channel strategy and expanding partnerships to capture market share.In its international business, Mayne Pharma will pursue targeted investment and new manufacturing revenue streams.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.15 |
Change
0.130(2.59%) |
Mkt cap ! $418.4M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.17 | $5.05 | $571.9K | 111.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $5.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.17 | 490 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |